Screener
Allogene Therapeutics ALLO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued and other current liabilities | (5,101) | (5,223) |
| Operating lease liabilities | (2,202) | (1,833) |
| Other long-term liabilities | 316 | 164 |
| Net cash used in operating activities | (12,913) | (52,929) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (9) | (99) |
| Proceeds from maturities of investments | 72,115 | 56,500 |
| Purchase of investments | (101,694) | (50,225) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's operating cash flow?
- Allogene Therapeutics (ALLO) reported operating cash flow of -$12.91M in Q1 2026.
- How has Allogene Therapeutics's operating cash flow changed year-over-year?
- Allogene Therapeutics's operating cash flow increased by 75.6% year-over-year, from -$52.93M to -$12.91M.
- What is the long-term trend for Allogene Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Allogene Therapeutics's operating cash flow has grown at a -5.2% compound annual growth rate (CAGR), from -$184.81M to -$149.25M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Allogene Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude